{"title":"骨质疏松症的治疗现在在哪里?","authors":"Ignac Fogelman","doi":"10.12968/hmed.2005.66.5.18422","DOIUrl":null,"url":null,"abstract":"<p><p>Osteoporosis is a metabolic bone disorder, leading to bone fragility and fracture. Recent guidance from the National Institute for Clinical Excellence (NICE) emphasizes the importance of secondary prevention of fragility fractures in postmenopausal women. What impact can the expanding range of treatments make on the growing and costly burden of osteoporosis?</p>","PeriodicalId":79637,"journal":{"name":"Hospital medicine (London, England : 1998)","volume":"66 5","pages":"284-7"},"PeriodicalIF":0.0000,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.12968/hmed.2005.66.5.18422","citationCount":"1","resultStr":"{\"title\":\"Where now for the management of osteoporosis?\",\"authors\":\"Ignac Fogelman\",\"doi\":\"10.12968/hmed.2005.66.5.18422\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Osteoporosis is a metabolic bone disorder, leading to bone fragility and fracture. Recent guidance from the National Institute for Clinical Excellence (NICE) emphasizes the importance of secondary prevention of fragility fractures in postmenopausal women. What impact can the expanding range of treatments make on the growing and costly burden of osteoporosis?</p>\",\"PeriodicalId\":79637,\"journal\":{\"name\":\"Hospital medicine (London, England : 1998)\",\"volume\":\"66 5\",\"pages\":\"284-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.12968/hmed.2005.66.5.18422\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hospital medicine (London, England : 1998)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12968/hmed.2005.66.5.18422\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital medicine (London, England : 1998)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12968/hmed.2005.66.5.18422","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Osteoporosis is a metabolic bone disorder, leading to bone fragility and fracture. Recent guidance from the National Institute for Clinical Excellence (NICE) emphasizes the importance of secondary prevention of fragility fractures in postmenopausal women. What impact can the expanding range of treatments make on the growing and costly burden of osteoporosis?
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
